Alpha-linolenic acid metabolic pathway enzymes

The phrase “Alpha-linolenic acid metabolic pathway enzymes” refers to a **set of enzymes** that participate in the metabolism of the essential omega‑3 fatty acid alpha‑linolenic acid (ALA), rather than a single, well-defined molecular target. ALA (18:3n‑3) is converted through a series of desaturation and elongation reactions in the endoplasmic reticulum and peroxisomes to longer‑chain omega‑3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA, 20:5n‑3) and docosahexaenoic acid (DHA, 22:6n‑3). Reactome and pathway databases describe this as a pathway comprising multiple enzymes, notably delta‑6 desaturase (fatty acid desaturase 2, FADS2) and delta‑5 desaturase (fatty acid desaturase 1, FADS1), along with elongation of very long chain fatty acid proteins (e.g., ELOVL5) and peroxisomal β‑oxidation enzymes, which collectively transform ALA through intermediates such as stearidonic acid and eicosatetraenoic acid to EPA and ultimately to DHA.[1][2][3][6] Because this term denotes an entire metabolic pathway rather than a single receptor, enzyme, transporter, or other discrete macromolecular entity, it is not typically treated as a single therapeutic “target” in drug discovery. Nonetheless, modulation of ALA metabolism—via diet, genetic variation in desaturases/elongases, or indirect pharmacologic effects—can influence tissue levels of EPA and DHA, which are precursors to anti‑inflammatory and cardio‑protective lipid mediators and have been implicated in cardiovascular disease, inflammation, and cancer biology.[1][3][5][6] Clinical and experimental studies more commonly focus on individual enzymes like FADS1, FADS2, or downstream eicosanoid/resolvin pathways as potential targets, rather than on the entire ALA metabolic pathway as a single drug target.

Other names

Alpha-linolenic acid metabolism enzymesAlpha-linolenic acid (ALA) metabolism pathway enzymesOmega-3 fatty acid biosynthesis enzymesAlpha-linolenic acid metabolic pathway